Mirabaud & Cie SA Has $712,000 Holdings in Stryker Corporation $SYK

Mirabaud & Cie SA decreased its position in Stryker Corporation (NYSE:SYK) by 66.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,925 shares of the medical technology company’s stock after selling 3,810 shares during the quarter. Mirabaud & Cie SA’s holdings in Stryker were worth $712,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Consolidated Portfolio Review Corp boosted its position in Stryker by 4.2% during the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock worth $256,000 after acquiring an additional 26 shares during the last quarter. Princeton Global Asset Management LLC lifted its position in shares of Stryker by 16.9% in the second quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after purchasing an additional 26 shares in the last quarter. Sunflower Bank N.A. boosted its holdings in Stryker by 4.0% during the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock worth $275,000 after purchasing an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC grew its position in Stryker by 3.2% in the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after purchasing an additional 27 shares in the last quarter. Finally, Sachetta LLC lifted its position in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Royal Bank Of Canada reissued an “outperform” rating and set a $435.00 price target on shares of Stryker in a research report on Friday, November 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a report on Monday. Evercore ISI decreased their target price on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. UBS Group set a $408.00 price target on shares of Stryker in a research note on Monday, October 13th. Finally, Barclays boosted their price objective on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Thirteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $431.84.

Stryker Price Performance

Shares of SYK opened at $354.54 on Friday. The company’s 50-day moving average is $364.19 and its 200-day moving average is $376.74. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The firm has a market capitalization of $135.58 billion, a PE ratio of 46.59, a PEG ratio of 2.51 and a beta of 0.89. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last announced its earnings results on Friday, October 31st. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. Stryker’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.87 EPS. Equities analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. This is a positive change from Stryker’s previous quarterly dividend of $0.84. Stryker’s payout ratio is currently 44.15%.

Insiders Place Their Bets

In other Stryker news, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer owned 6,694 shares of the company’s stock, valued at $2,449,200.72. The trade was a 2.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the transaction, the chief accounting officer directly owned 2,833 shares in the company, valued at $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 522,118 shares of company stock worth $185,381,932 in the last 90 days. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.